ArticleAIDS (London, England)2021
Initiating antiretroviral treatment for newly diagnosed HIV patients in sexual health clinics greatly improves timeliness of viral suppression.
Article in AIDS (London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 31 citations in OpenAlex.
- Association Between Alcohol Use, CD4 Count, and Depressive Symptoms Among People with HIV with Viral Load Suppressed in Southwestern Uganda.AIDS and behavior · 2026Article
- Efficacy and safety of bictegravir, emtricitabine, and tenofovir alafenamide (BIC/FTC/TAF) versus efavirenz, lamivudine, and tenofovir disoproxil fumarate (EFV+3TC + TDF) in late-presenting people with HIV rapid initial antiretroviral therapy.BMC infectious diseases · 2026Article
- Outcomes of Rapid Restart Among People With Previously Diagnosed HIV at a Safety-Net HIV Clinic in San Francisco.Journal of acquired immune deficiency syndromes (1999) · 2025Article
- Socio-ecological Determinants of Detectable Viremia among Pregnant People Living with HIV in South Brazil: The Role of Stimulant Use Disorder and Homelessness.AIDS and behavior · 2025Article
- Multiparametric Immune Profiles and Their Potential Role in HIV-1 Disease Progression and Treatment.Pathogens (Basel, Switzerland) · 2025Article
- Implementation of adolescent HIV screening in two urban pediatric emergency departments in the United States.PloS one · 2025Article
- Real world community-based HIV Rapid Start Antiretroviral with B/F/TAF versus prior models of antiretroviral therapy start - the RoCHaCHa study, a pilot study.AIDS research and therapy · 2024Observational
- Immediate initiation of antiretroviral treatment: knowledge, attitudes, and practices among clinic staff in New York City.BMC health services research · 2023Article
- The Rapid interaction: a qualitative study of provider approaches to implementing Rapid ART.Implementation science communications · 2023Article
- Test, treat, and maintain: rapid initiation of antiretroviral therapy.AIDS (London, England) · 2021Article
- Provider Perspectives on Rapid Treatment Initiation Among People Newly Diagnosed With HIV: A New Message of "Urgency"?Journal of the International Association of Providers of AIDS CareArticle
Corrections and comments
- Commented on by
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe 'JumpstART' program in New York City (NYC) public Sexual Health Clinics (SHC) provides patients newly diagnosed with human immunodeficiency virus (HIV) with antiretroviral medication (ART) (1-month supply) on day of diagnosis and active linkage to HIV care (LTC). We examined viral suppression (VS) among patients who did and did not receive JumpstART services.
designRetrospective cohort.
methodsAmong newly diagnosed SHC patients (23 November 2016-30 September 2018) who were matched to the NYC HIV surveillance registry to obtain HIV laboratory test results through 30 June 2019, we compared 230 JumpstART and 73 non-JumpstART patients regarding timely LTC (≤30 days), probability of VS (viral load < 200 copies/ml) by 3 months post-diagnosis, and time to and factors associated with achieving VS within the follow-up period.
resultsOf 303 patients, 76% (230/303) were JumpstART and the remaining were non-JumpstART patients; 36 (11%) had acute HIV infections. LTC ≤30 days was observed for 63% of JumpstART and 73% of non-JumpstART patients. By 3 months post-diagnosis, 83% of JumpstART versus 45% of non-JumpstART patients achieved VS (log-rank, P < .0001). Median times to VS among virally suppressed JumpstART and non-JumpstART patients were 31 (interquartile range [IQR]: 24-51) and 95 days (IQR: 52-153), respectively. For groups with and without timely LTC, JumpstART was associated with viral suppression within 3 months post-diagnosis, after adjusting for age and baseline viral load.
conclusionsPrompt ART initiation among SHC patients, some with acute HIV infections, resulted in markedly shortened intervals to VS. Immediate ART provision and active LTC can be key contributors to improved HIV treatment outcomes and the treatment-as-prevention paradigm, with potential for downstream, population-level benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.